Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Today, ComplexCon announces its 2025 Global Artistic Director and festival dates, with the pioneering festival of convergence culture heading back to Hong Kong, March 21-23, 2025 and Las Vegas, NV, ...

The list of... at 21:30 Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis Aurinia Pharmaceuticals Inc. (Aurinia or the Company) commends the ...

There are multiple chapters near you. Select your preferred chapter.

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...

The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight ...

Discover how targeting E3-X ligase could revolutionize SLE treatment by enhancing anti-inflammatory effects while reducing ...